SCHEMBL7108930

SCHEMBL7108930

OC1CC(c2ccc(-c3ncccn3)cc2)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.43
HDAC4 P56524 2/20 0.42
CLK4 Q9HAZ1 1/20 0.40
ADRB2 P07550 1/20 0.40
KDM1A O60341 2/20 0.38
MAOB P27338 1/20 0.38
PRKAB2 O43741 2/20 0.36
PRKAG1 P54619 2/20 0.36
PRKAA2 P54646 2/20 0.36
PRKAA1 Q13131 2/20 0.36
PRKAG3 Q9UGI9 2/20 0.36
PRKAG2 Q9UGJ0 2/20 0.36
PRKAB1 Q9Y478 2/20 0.36
TNK2 Q07912 3/20 0.36
CYP2A6 P11509 1/20 0.34
ESR2 Q92731 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
HTR2B P41595 1/20 0.33
AOC3 Q16853 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7148291 0.81 MAOA (0.47) MAOAHDAC4CLK4ADRB2KDM1A
SCHEMBL7109799 0.81 MAOA (0.40) MAOAHDAC4CLK4ADRB2KDM1A
SCHEMBL7209332 0.81 CLK4 (0.44) MAOAHDAC4CLK4ADRB2KDM1A
SCHEMBL7107690 0.77 MAOA (0.38) MAOAHDAC4CLK4ADRB2KDM1A
SCHEMBL7103483 0.77 ADRB2 (0.49) MAOAHDAC4CLK4ADRB2KDM1A
SCHEMBL7209014 0.77 CLK4 (0.42) MAOAHDAC4CLK4ADRB2KDM1A
SCHEMBL7109624 0.74 GAA (0.46) MAOAHDAC4CLK4ADRB2KDM1A
SCHEMBL1200615 0.73 SLC18A3 (0.55)
SCHEMBL6685962 0.72 CLK4 (0.64) HDAC4CLK4ADRB2CYP2A6NPC1
SCHEMBL1626055 0.71 SLC18A3 (0.47) MAOAKDM1AMAOBCYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1343798-A1 6-O-CARBAMOYL KETOLIDE DERIVATIVES OF ERYTHROMYCIN USEFUL AS ANTIBACTERIALS Ortho-Mcneil Pharmaceutical, Inc. (US) 2003-09-17 EP disclosed
US-6613747-B2 Erythromycins to treat community-acquired pneumonia and upper and lower respiratory tract, skin and soft tissue, hospital-acquired lung, bone and joint infections; Staphyloccus; Enterococcus; Moraxella; Hemophilus; antibiotic resistance ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-09-02 US disclosed
US-20020115620-A1 6-0-carbamoyl ketolide antibacterials ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-08-22 US disclosed
WO-2002046204-A1 6-0-CARBAMOYL KETOLIDE DERIVATIVES OF ERYTHROMYCIN USEFUL AS ANTIBACTERIALS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115620-A1 6-0-carbamoyl ketolide antibacterials Q6ZSR9, HK1, KDM4E MAOA 4332/4885HDAC4 249/4885CLK4 3703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.